The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol plus metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.288, no.1, pp.213-220, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 288 Issue: 1
- Publication Date: 2013
- Doi Number: 10.1007/s00404-013-2742-y
- Journal Name: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.213-220
- Keywords: Polycystic ovary syndrome, Leptin, Ghrelin, Drospirenone-ethinyl estradiol, Metformin, POLYCYSTIC-OVARY, ULTRASOUND EXAMINATION, INSULIN-RESISTANCE, WOMEN, ENDOCRINE, OBESE, CONSENSUS, FEATURES, PCOS
- Acibadem Mehmet Ali Aydinlar University Affiliated: No
Abstract
Polycystic ovary syndrome (PCOS) is considered as the most common endocrinopathy among women of reproductive age. Oral contraceptives (OCs) and metformin are one of the main drug groups in the long-term treatment of PCOS. This study was undertaken to investigate the effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ultrasonographic markers, body fat mass (BFM) index, leptin-ghrelin.